Jennifer Adams
Family · Houston, TXNPI 1366914434
Payments from drug & device makers
Across 77 payments — averaging $20.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$151
- Vanda Pharmaceuticals Inc.$134
- Lilly USA, LLC$133
- Averitas Pharma Inc.$117
- Johnson & Johnson$114
- Novo Nordisk$113
- plus $841 from 24 others
What the payments were for
- Food & beverage$1,603100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 7 | $151 |
| Vanda Pharmaceuticals Inc. | 7 | $134 |
| Lilly USA, LLC | 7 | $133 |
| Averitas Pharma Inc. | 1 | $117 |
| Johnson & Johnson | 6 | $114 |
| Novo Nordisk | 5 | $113 |
| Stryker | 1 | $100 |
| Alkermes, Inc. | 4 | $75 |
| AbbVie | 4 | $75 |
| Xeris Pharmaceuticals, Inc. | 4 | $69 |
| GSK | 3 | $50 |
| Pfizer | 3 | $43 |
| Bayer | 2 | $40 |
| Antares Pharma, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Boehringer Ingelheim | 2 | $34 |
| AstraZeneca | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $28 |
| Currax Pharmaceuticals LLC | 2 | $24 |
| Corium, LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Exact Sciences | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Qutenza$117
How this compares
$1,603 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $42,186 |
| FarxigaDapagliflozin Propanediol | 25 | $25,755 |
| MounjaroTirzepatide | 17 | $17,864 |
| JardianceEmpagliflozin | 14 | $17,319 |
| LinzessLinaclotide | 13 | $7,023 |
| SymbicortBudesonide/Formoterol Fumarate | 20 | $4,752 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $2,727 |
| Ezetimibe | 55 | $1,566 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,467 |
| Diclofenac Potassium | 55 | $1,250 |
| Gabapentin | 78 | $1,093 |
| Atorvastatin Calcium | 158 | $1,008 |
| Omeprazole | 59 | $859 |
| Hydroxyzine Hcl | 43 | $858 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $841 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $113 | $42,18642 claims |
| AstraZenecaFarxiga, Symbicort | $28 | $30,50745 claims |
| Lilly USA, LLCMounjaro | $133 | $17,86417 claims |
| Boehringer IngelheimJardiance | $34 | $17,31914 claims |
| AbbVieLinzess | $75 | $7,02313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.
Other family in Houston
- Lashonda CraneHouston$3.4M
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- David WeirDallas$959K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.